CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the initiation of toxicology studies conducted under Good Laboratory Practice (GLP) standards for its lead product candidate, CMP-S ...

Core Viewpoint - CAMP4 Therapeutics Corporation (CAMP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - For CAMP, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to a higher stock price [5]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of CAMP to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating superior earnings estimate revisions and potential for market-beating returns [10]. Earnings Estimate Details - CAMP is projected to earn -$1.71 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for CAMP has increased by 31%, reflecting analysts' growing confidence in the company's earnings potential [8].

Upgrades - Loop Capital upgraded Union Pacific (UNP) to Hold from Sell with a price target of $227, up from $214, noting that the shares are down 5% year-to-date and valuation multiples are modestly above their five-year ranges [2] - BofA upgraded Prologis (PLD) to Buy from Neutral with a price target of $130, up from $118, highlighting improved conversion rates of new lease proposals into signed leases during Q3 compared to Q2, and an optimistic outlook for demand versus supply dynamics through 2026 [3] - Goldman Sachs upgraded Hershey (HSY) to Buy from Sell with a price target of $222, up from $170, citing a compelling risk/reward scenario following multiple guidance reductions over the past year [4] - Arete upgraded Baidu (BIDU) to Buy from Sell with a price target of $143, emphasizing the potential of Baidu's Kunlun chip venture to offset challenges in its online advertising business due to AI chip shortages in China [5] - Citizens JMP upgraded CoreWeave (CRWV) to Outperform from Market Perform with a price target of $180, projecting significant growth for its graphics processing unit-as-a-service business from $3B-$4B to an estimated $300B [4] Downgrades - TD Cowen downgraded Warner Bros. Discovery (WBD) to Hold from Buy with an unchanged price target of $14, expressing concerns about the stock's risk/reward profile following a recent rally and potential bid from Paramount Skydance [6] - Rothschild & Co Redburn downgraded Live Nation (LYV) to Neutral from Buy with a price target of $170, up from $144, indicating that margin expansion will slow from fiscal 2026, limiting upside potential to earnings estimates [6] - Stifel downgraded VF Corp. (VFC) to Hold from Buy with a price target of $16, up from $15, stating that the stock's risk-reward is now balanced after a 12.5% one-month return, despite a strong outcome from the $600M sale of Dickies [6] - JPMorgan downgraded Camp4 Therapeutics (CAMP) to Neutral from Overweight without a price target, noting that while the company has a cash runway into 2027, its lead program is in the early stages [6] - JPMorgan downgraded Neumora Therapeutics (NMRA) to Underweight from Neutral without a price target, citing a failed Phase 3 trial for its navacaprant treatment in major depressive disorder [6]

Upgrades - Loop Capital upgraded Union Pacific (UNP) to Hold from Sell with a price target of $227, increased from $214, noting shares are down 5% year-to-date and valuation multiples are modestly above five-year lows [2] - BofA upgraded Prologis (PLD) to Buy from Neutral with a price target of $130, up from $118, citing improved lease conversion rates in Q3 compared to Q2 and positive demand-supply dynamics expected through 2026 [3] - Goldman Sachs upgraded Hershey (HSY) to Buy from Sell with a price target of $222, raised from $170, highlighting a compelling risk/reward scenario after multiple guidance reductions [4] - Arete upgraded Baidu (BIDU) to Buy from Sell with a price target of $143, emphasizing the potential of Baidu's Kunlun chip venture to offset challenges in its online advertising business [5] - Citizens JMP upgraded CoreWeave (CRWV) to Outperform from Market Perform with a price target of $180, projecting growth of its GPU-as-a-service business to an estimated $300 billion from $3 billion to $4 billion currently [4] Downgrades - TD Cowen downgraded Warner Bros. Discovery (WBD) to Hold from Buy with an unchanged price target of $14, expressing concerns about the stock's risk/reward after a recent rally [6] - Rothschild & Co Redburn downgraded Live Nation (LYV) to Neutral from Buy with a price target of $170, up from $144, indicating slower margin expansion and reduced earnings upside potential [6] - Stifel downgraded VF Corp. (VFC) to Hold from Buy with a price target of $16, increased from $15, stating that the stock's risk-reward is now balanced after a 12.5% one-month return [6] - JPMorgan downgraded Camp4 Therapeutics (CAMP) to Neutral from Overweight without a price target, noting early-stage challenges in its lead program despite a cash runway into 2027 [6] - JPMorgan downgraded Neumora Therapeutics (NMRA) to Underweight from Neutral without a price target, citing a failed Phase 3 trial for its treatment in major depressive disorder [6]

Financing Overview - CAMP4 Therapeutics has secured a private placement financing of up to $100 million, with an initial $50 million in upfront proceeds to fund the SYNGAP1 program and general corporate purposes [1][2] - The financing includes the issuance of 26,681,053 shares of common stock at $1.53 per share, along with additional shares and pre-funded warrants contingent on achieving specific milestones [2][4] Clinical Development - The funds will support the Phase 1/2 clinical trial for SYNGAP1-related disorders, expected to start in the second half of 2026 [1][2] - The company aims to develop a first-in-class treatment targeting gene expression to address genetic diseases [2][9] Management Changes - Doug Williams, Ph.D., has been appointed as Board Chair, and Dan Tardiff, Ph.D., has been elevated to Chief Scientific Officer [3][5] - The board has seen resignations and transitions, with a focus on enhancing leadership in drug discovery and development [3][5] Investor Participation - The financing is led by Coastlands Capital, with participation from both new and existing investors, including Janus Henderson Investors and Balyasny Asset Management [4] - Leerink Partners is acting as the lead placement agent, supported by other financial institutions [4] Company Background - CAMP4 Therapeutics focuses on developing RNA-targeting therapeutics to restore healthy protein levels for a range of genetic diseases [9] - The company utilizes its proprietary RAP Platform to identify and target regulatory RNAs associated with various genetic disorders [9]

Core Insights - CAMP4 Therapeutics presented positive translational data from its SYNGAP1-related disorders program, demonstrating efficacy in a humanized mouse model and increased protein levels in non-human primates at the ASGCT Annual Meeting [1][7] - The company reported a net loss of $12.6 million for Q2 2025, consistent with the loss from the same quarter in 2024 [8][13] - CAMP4 is advancing its CMP-SYNGAP-01 program with plans to initiate GLP toxicology studies in Q3 2025 and a potential global Phase 1/2 clinical trial in SYNGAP patients in H2 2026 [2][6] Corporate Highlights - The company has a strong pipeline focused on regulatory RNA-targeting therapeutics aimed at treating genetic diseases [1][9] - CMP-CPS-001 is being developed as a first-in-class, disease-modifying therapy for common urea cycle disorders (UCDs), with safety and biomarker data expected in Q4 2025 [2][6] Financial Results - As of June 30, 2025, CAMP4 had cash, cash equivalents, and marketable securities totaling $39.1 million, down from $49.3 million as of March 31, 2025 [4][13] - Research and development expenses for Q2 2025 were $10.3 million, an increase from $9.4 million in Q2 2024, primarily due to higher clinical and preclinical study costs [4][13] - General and administrative expenses rose to $4.2 million in Q2 2025 from $3.3 million in Q2 2024, driven by increased personnel-related and overhead costs [5][13]

Core Viewpoint - CAMP4 Therapeutics Corporation reported strong execution in Q1 2025, advancing its clinical studies and achieving significant milestones in its therapeutic pipeline [2][4]. Corporate Highlights - The Phase 1 clinical trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data are expected in Q4 2025 [4][5]. - A Clinical Trial Application (CTA) was successfully submitted in Europe for a Phase 1b clinical trial targeting female OTC heterozygotes [4][5]. - The company nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders, with GLP toxicology studies expected to begin in 2025 [4][6]. - CAMP4 will present at the American Society of Cell and Gene Therapy (ASGCT), showcasing data on increased SYNGAP1 protein levels from CMP-SYNGAP-01 and interim safety results from the Phase 1 study of CMP-CPS-001 [4][5]. Financial Results - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $49.3 million, down from $64.0 million as of December 31, 2024 [7]. - Research and development expenses for Q1 2025 were $10.1 million, an increase from $9.7 million in Q1 2024, primarily due to higher clinical and preclinical study costs [7]. - General and administrative expenses rose to $3.8 million in Q1 2025 from $3.1 million in Q1 2024, attributed to increased personnel-related and overhead expenses [8]. - The net loss for Q1 2025 was $12.4 million, slightly improved from a net loss of $12.5 million in Q1 2024 [8][14].

Core Insights - CAMP4 Therapeutics is focused on developing regulatory RNA-targeting therapeutics aimed at upregulating gene expression to restore healthy protein levels for treating various genetic diseases [1][3] - The company will present three oral presentations at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, highlighting their research and interim safety data from their Phase 1 clinical trial of CMP-CPS-001 [1][2] Group 1: Presentations Details - The first presentation will discuss targeting regulatory RNAs with antisense oligonucleotides for the potential treatment of urea cycle disorders, presented by Dan Tardiff, Ph.D. on May 16, 2025 [2] - The second presentation will also be by Dan Tardiff, Ph.D., focusing on the potential treatment of SYNGAP1-related disorders, scheduled for the same session [2] - The third presentation will provide interim safety readouts from a first-in-human double-blind, placebo-controlled study of CMP-CPS-001, presented by Yuri Maricich, M.D. on May 16, 2025 [2] Group 2: Company Overview - CAMP4 Therapeutics is developing disease-modifying treatments for over 1,200 genetic diseases where increasing healthy protein levels may provide therapeutic benefits [3] - The company's proprietary RAP Platform™ is designed to map regulatory RNAs and generate therapeutic candidates targeting regRNAs associated with haploinsufficient and recessive partial loss-of-function disorders [3]

Core Insights - CAMP4 Therapeutics is advancing its clinical programs, particularly focusing on CMP-CPS-001 for Urea Cycle Disorders (UCDs) and has initiated a Phase 1b trial for female OTC heterozygotes, addressing an underserved patient population [2][3][11] - The company has nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders, with promising preclinical data supporting its potential [2][11] - Financial results for the year ended December 31, 2024, show a net loss of $51.8 million, with cash and cash equivalents of approximately $64.0 million, sufficient to fund operations into Q2 2026 [6][7][8] Clinical Development - The Phase 1 clinical trial of CMP-CPS-001 in UCDs is ongoing, with dosing completed in two of four multiple ascending dose cohorts, and safety data expected in Q4 2025 [1][4] - The planned expansion into a Phase 1b clinical trial in female OTC heterozygotes is anticipated to begin in Q2 2025, with a Clinical Trial Application (CTA) to be submitted in Europe [2][11] - Recent studies indicate that female carriers of OTC deficiency may experience significant health risks, prompting a shift from passive observation to proactive treatment [3][11] Financial Performance - Research and development expenses for 2024 were $38.8 million, a decrease from $40.6 million in 2023, primarily due to reduced clinical and preclinical costs [6] - General and administrative expenses increased to $14.9 million in 2024 from $11.6 million in 2023, attributed to higher personnel-related costs [7] - The company reported a net loss of $51.8 million for 2024, compared to a loss of $49.3 million in 2023, with a net loss per share of $11.04 [7][15] Cash Position - As of December 31, 2024, CAMP4 had cash and cash equivalents of approximately $64.0 million, which is expected to support its planned activities into Q2 2026 [8][15] - The company’s total assets increased to $78.3 million in 2024 from $54.9 million in 2023, while total liabilities decreased slightly [15] Strategic Initiatives - CAMP4 is focusing on expanding its strategic partnerships to enhance the value of its RAP Platform, which targets regulatory RNAs to amplify gene expression [11] - The company has initiated a discovery program for GBA1-related Parkinson's Disease, with ongoing preclinical studies to identify a development candidate [11]

Core Insights - CAMP4 Therapeutics Corporation has appointed Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to its Board of Directors to enhance its strategic guidance in drug development efforts [1][2] - The company focuses on developing regRNA-targeting antisense oligonucleotide (ASO) therapies aimed at upregulating gene expression to restore healthy protein levels [1][4] Company Overview - CAMP4 is a clinical-stage biotechnology company developing disease-modifying treatments for a range of genetic diseases where increasing healthy protein levels may provide therapeutic benefits [4] - The proprietary RAP Platform™ allows for targeted gene upregulation by mapping regRNAs, which are crucial in controlling gene expression [4] Leadership Expertise - Dr. Doug E. Williams has over 30 years in the biopharma industry and has contributed to the development of transformative drugs such as LEUKINE, ENBREL, and SPINRAZA [2][3] - Dr. Murray Stewart has extensive clinical development experience, having served as Chief Medical Officer at Rhythm Pharmaceuticals and held leadership roles at GlaxoSmithKline [3] Strategic Focus - The company aims to advance its lead clinical program for urea cycle disorders and preclinical program for SYNGAP1-related disorders while developing additional RNA-targeting medicines [2] - The focus is on addressing diseases where modest increases in protein levels can significantly impact patient lives [2]